Time filter

Source Type

PubMed | Beijing Institute for Cancer Research, Sun Yat Sen University, Dalian Medical University, Shantou University and 13 more.
Type: Journal Article | Journal: Archives of medical science : AMS | Year: 2014

The aim of this study was to compare the efficacy and toxicity of dicycloplatin plus paclitaxel with those of carboplatin plus paclitaxel as first-line treatment for patients with advanced non-small-cell lung cancer (NSCLC).In this study, 240 NSCLC patients with stage IIIB (with pleural effusion) and stage IV disease were randomly assigned (1: 1) to receive dicycloplatin 450 mg/m(2) or carboplatin AUC = 5, in combination with paclitaxel 175 mg/m(2) (D + P or C + P) every 3 weeks for up to 4 to 6 cycles. The primary endpoint was response rate. Secondary endpoints included progression-free survival (PFS), overall survival (OS) and adverse events.The response rates for the D + P and C + P arm were 36.44% and 30.51%, respectively (p = 0.33). The median PFS was 5.6 months in the D + P arm and 4.7 months in the C + P arm (p = 0.31). The median OS was 14.9 months for D + P and 12.9 months for C + P (p = 0.37). Adverse events in the two arms were well balanced. The most common grade 3/4 adverse event was hematologic toxicity.Patients treated with D + P had similar response and survival rates to those treated with C + P, and toxicities of both treatments were generally tolerable.


Huang Z.-Z.,U.S. Center for Disease Control and Prevention | Chen W.-Q.,Chinese Academy of Sciences | Wu C.-X.,U.S. Center for Disease Control and Prevention | Zheng R.-S.,Chinese Academy of Sciences | And 5 more authors.
Tumor | Year: 2012

Objective: To describe the incidence and mortality of female breast cancer in China during 2003-2007. Methods: The incidence and mortality data of female breast cancer and the corresponding population data from 32 eligible cancer registries in China during 2003-2007 were collected and analyzed. Results: The combined crude incidence rate of female breast cancer during 2003-2007 was 41.64 per 100 000, which was the highest among female cancer incidence rates. The combined crude mortality rate of female breast cancer was 9.63 per 100 000, which was ranked as the sixth among the mortality rates of all female cancers. The incidence rate was 3.04 times higher and the mortality rate was 1.92 times higher in urban areas than those in rural areas. Compared to the incidence and mortality rates of 184 regions provided from GLABOCAN 2008 database, the female breast cancer incidence in China was ranked as the one hundred and tenth, and the mortality was ranked as the one hundred and seventy-second. Conclusion: Breast cancer has been becoming one of the most common cancers among Chinese women. The incidence and mortality rates of female breast cancer in urban areas are significantly higher than those in rural areas, although the overall incidence and mortality rates of breast cancer in Chinese women are still at a medium or low level in the world. © 2012 by Tumor.


The present invention discloses a method for predicting the ability of tumor invasion and metastasis in vitro, including detecting methylation of the cytosine in 5 CpG island of DNA sequence of serum response factor. In addition, the present invention also provides four artificial nucleotide fragments for detection of methylation of the cytosine in CpG island of the nucleotide sequence of serum response factor.


A method of detection of occurrence of cancers comprising:Extracting tissue or plasma free DNA from cancer and non-cancer patients;Detecting and calculating proportion of methylated or demethylated GFRa1 CpG islands; setting a cutoff value using the proportion of methylated or demethylated GFRa1;Extracting tissue or plasma free DNA samples from testing subjects in vitro, detecting and calculating proportion of methylated or demethylated GFRa1 CpG islands in samples;Comparing proportion of methylated or demethylated GFRa1 from step c) with the cutoff value from step b);If proportion of methylated GFRa1 from step c) is less than or equal to cutoff value from step b), the occurrence of cancer is considered, otherwise, it is not; or, if the proportion of demethylated GFRa1 from step c) is higher than or equal to cutoff value from step b), the occurrence of cancer is considered, otherwise it is not considered.


Patent
BGI Technology Solutions Co. and Beijing Institute For Cancer Research | Date: 2015-09-29

The present invention relates to methods, kits, and compositions for detecting and/or diagnosing metastatic potential of cancer cells or for evaluating prognosis in a patient with cancer by detection of the protein expression level of an HLA class I molecule and/or the copy number variation of a polynucleotide encoding the HLA class I molecule. The present invention also relates to the use of the protein expression level of an HLA class I molecule and/or the copy number variation of a polynucleotide encoding the HLA class I molecule as a prognosis biomarker and metastasis predictive biomarker of cancer.


Patent
Beijing Institute For Cancer Research | Date: 2012-02-22

Disclosed is a method for searching, identifying, or validating a marker CACNA2D1 of tumor-initiating cells. The method comprises a step of immuninizing an animal using HEP-12 cells originating from a recurrent tumor and rich in originating cells. Also disclosed is a monoclonal antibody specially recognizing CACNA2D1 or antigen-binding fragments thereof, and the use thereof for treating or preventing tumors or diseases or conditions related to CACNA2D1.


The invention provides a primer group for detecting CpO island methylation of p16 gene using methylation specific fluorescence technique. The primer group comprises a pair of oligonucleotide primers and a fluorescence-labeled probe. Said oligonucleotide primer pair has base sequence represented by SEQ ID NO.1 and SEQ ID NO.2. Said fluorescence-labeled probe has base sequence represented by SEQ ID NO.3 or SEQ NO.4.


Provided in the present invention are a method using in vitro measurement of the content of methylation or demethylation of GFRal CpG islands to estimate a risk of tumorigenesis and of tumor metastasis, or postoperative life expectancy, and a nucleotide sequence used.


The invention provides a primer group for detecting CpG island methylation of p16 gene using methylation specific fluorescence technique. The primer group comprises a pair of oligonucleotide primers and a fluorescence-labeled probe. Said oligonucleotide primer pair has base sequence represented by SEQ ID NO: 1 and SEQ ID NO: 2. Said fluorescence-labeled probe has base sequence represented by SEQ ID NO: 3 or SEQ ID NO: 4.


Patent
Beijing Institute For Cancer Research | Date: 2014-01-08

Disclosed is a method for searching, identifying, or validating a marker CACNA2D1 of tumor-initiating cells. The method comprises a step of immunizing an animal using HEP-12 cells originating from a recurrent tumor and rich in originating cells. Also disclosed is a monoclonal antibody specially recognizing CACNA2D 1 or antigen-binding fragments thereof, and the use thereof for treating or preventing tumors or diseases or conditions related to CACNA2D1.

Loading Beijing Institute for Cancer Research collaborators
Loading Beijing Institute for Cancer Research collaborators